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Abstract
Ulcerative colitis, primary sclerosing
cholangitis, and anti-glomerular basement
membrane disease (anti-GBM) are three rare
immune diseases with incompletely under-
stood pathogenic mechanisms. We describe
here the case of a 29-year-old man with ulcer-
ative colitis and primary sclerosing cholang -
itis who, eight years later, developed anti-
GBM disease with destruction of all glomeruli
leading to end-stage kidney disease.
Association of these three immune diseases
in the same patient has never been described.
Because HLA-mediated susceptibility cannot
be incriminated completely in our case, we
hypothesize that environmental factors or
previous immunosuppressive treatment used
might be the link.
Introduction
Anti-glomerular basement membrane (anti-
GBM) disease is mediated by auto-antibodies,
leading to crescentic glomerulonephritis.1
Ulcerative colitis (UC) is a chronic inflamma-
tory bowel disease (IBD), the cause of which
is incompletely understood but may be
immunologic.2 Primary sclerosing cholangitis
(PSC) is a cholestatic liver disease often asso-
ciated with UC. 
Here, we describe a patient who developed
first UC and PSC and, a few years later, anti-
GBM glomerulonephritis. This case raises the
question of whether this is a coincidence or
whether there is a link between these three
diseases.
Case Report
Mr B., a 29-year-old white man, was admit-
ted because he complained of a high fever
lasting for two weeks, without any other clin -
ical sign except herpetic keratitis (treated
with valacyclovir for seven days). His past
medical history included UC eight years earli-
er (with a histological diagnosis and p-ANCA
detected by indirect immunofluoresence but
without specificity detected by the ELISA test).
He had been treated successively with 5-
aminosalicylic acid, steroids for approximately
three years (with high corticodependence),
azathioprine for one month (gastrointestinal
intolerance), infliximab (nine infusions inef-
fective), and finally a complete colectomy six
years previously. UC was associated with a
liver biopsy-proved PSC (biopsy performed six
years before for anicteric cholestasis). He also
presented with cutaneous biopsy-proved
lichen planus. Since the colectomy and during
the six years, he did not require any therapy.
An initial blood test showed a serum creati-
nine of 113 mmol/L and an increased C-reat -
ive protein (CRP) of 103 mg/L. Because of a
persistent high fever, after four days our
patient was referred to the emergency unit.
Blood tests showed acute renal failure (cre-
atinine: 507 mmol/L; urea: 17.9 mmol/L) with
inflammatory syndrome (CRP: 294 mg/L;
white blood cell count: 14,900 G/L). At the
time of admission, Mr B. was febrile at 40°C
and his blood pressure was 150/90 mmHg.
Apart from cutaneous lichen planus, the clin-
ical examination was unremarkable. He was
oliguric; his stools were abundant as usual.
Urinalysis showed 3+ blood and 3+ protein,
with proteinuria quantified at 1.17g/L on olig-
uric diuresis. Serum creatinine increased up
to 800 mmol/L; the blood picture showed
hemoglobin 12.8 g/dL, white blood cell count
18,800 G/L, platelets 503,000 G/L, and CRP
increased up to 320 mg/L. Oxygen saturation
and the thoracic CT-scan were normal. 
A complete search for infectious disease,
with urine and blood cultures for bacterial
and fungal infections (including BK), and
serology and PCR for viral infection, as well as
stool cultures and a chest X-ray, was negative.
Anti-GBM antibodies were positive (32
UI/mL). ANCA were positive on immunofluo-
rescence but without any specificity with
ELISA testing. Antinuclear factor was 1/160
flecked with anti-SSA; the complement pro-
teins assay was normal; plasma protein elec-
trophoresis revealed hypoalbuminemia (24
g/L) and elevated a-globulins. A renal biopsy
showed extensive exuberant crescent with
necrotizing changes in 90% of glomeruli
(Figure 1). Glomerular tufts were consider-
ably compressed with thrombonecrosis. The
interstitium and tubules had inflammatory
edema. Immunofluorescence revealed linear
deposition of IgG along capillary loops. His
MHC gene was typed: A1A3 B8B40 DRB1*01,
DRB1*03, DQB1*02, DQB1*05.
Owing to the clinical severity and our
patient’s young age, despite the poor histo -
logical prognosis, Mr B. received three pulses
of methylprednisolone followed by oral pred-
nisolone and cyclophosphamide (2 mg/kg
daily). Plasma exchange was performed daily
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for 15 days (5L plasma per treatment, albumin
plus hydroxyethylamidon as replacement
fluid). At the same time, renal replacement
therapy was started. Despite immunosuppres-
sive therapy and plasma exchanges, Mr B.
remained on hemodialysis.
Discussion
This association of three severe immune
diseases in the same young patient is intrigu-
ing. The first association of UC and anti-GBM
glomerulonephritis was described in one child
who developed an UC four years after his renal
transplantation for end-stage renal disease
owing to anti-GBM disease.3 The authors
hypothesized that HLA DR2 homozygosity may
have predisposed to both immune diseases.
Nakamura et al. described the case of a woman
who developed UC 19 months after the onset of
anti-GBM disease.4 She was also homozygous
for the DR2 allele. Plaisier et al. reported a
patient who developed anti-GBM nephritis and
bullous pemphigoid in the context of Crohn’s
disease relapse.5 The authors hypothesized
that an infectious aggression can result in a
simultaneous relapse of Crohn’s disease and
exposure of the Goodpasture antigenic site
recognized as foreign. Finally, our case is the
fourth reported case and the first one associat-
ed with PSC. Our case raises the question: is
there a relationship between UC, PSC, and
anti-GBM nephropathy? 
The first link might be the HLA susceptibil-
ity. There is indeed a strong association
between anti-GBM disease and the HLA-DR2
gene, which is present in approximately 80%
of cases.6 However, contrary to the first two
described cases, the HLA genotype of our
patient was not DR2. A study revealed a neu-
tral association of DRB1*03 (carried by our
patient) but a decreased frequency of
DRB1*01 (also carried by our patient) in anti-
GBM nephritis.7 The DRB1*03 is known to
confer a high risk to develop PSC but less risk
of UC.8 Therefore, our patient’s HLA genotype
cannot easily explain the association of these
immune diseases. The second link might be
trigger factors such as drugs or upper respira-
tory infection. However, in our case like in the
first two other cases, diseases were not simul-
taneous but separate by years. Mr B. did have
an HSV infection that might have triggered the
glomerulopathy but he did not have it when he
developed UC. In IBD, lymphocytes activated by
bacterially-derived antigens can transfer to the
kidneys and cause inflammation that leads to
exposure of the Goodpasture antigenic site.9
However, because our patient was colec-
tomised, he no longer presented with colitis,
which makes this triggering mechanism
unlikely. Thirdly, another hypothesis could be
that previous immunosuppressive therapy
received by Mr B. changed his profile of
autoantibody response. In the case described
by Hibbs et al.,3 the patient also developed an
autoimmune disease while on post-transplant
immunosuppressive therapy. However, despite
the large number of patients under immuno-
suppressive therapy for organ transplant -
ations, very few developed IBD, likewise plead-
ing against this hypothesis. There are some
reports of autoimmune processes developing
after infliximab therapy; principally cutaneous
vasculitis, lupus, and interstitial lung disease,
but no glomerulonephritis to date.10 Is inflix-
imab the link for our patient? 
In conclusion, we present the fourth case of
the association of anti-GBM disease and UC,
and the first one associated with PSC. The
HLA genotype, or an environmental or infec-
tious trigger, or long-term previous immuno-
suppressive treatment (except for treatment
with infliximab) does not seem to be the link.
Thus, it there a link or is it coincidence? 
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Figure 1. Abundant necrotizing changes with the glomerular tuft entirely compressed by
a voluminous crescent. (High-power; trichrome stain.)
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